How to fully protect the kidney in a severe model of progressive nephropathy: A multidrug approach

Carla Zoja, Daniela Corna, Davide Camozzi, Dario Cattaneo, Daniela Rottoli, Cristian Batani, Cristina Zanchi, Mauro Abbate, Giuseppe Remuzzi

Research output: Contribution to journalArticle

132 Citations (Scopus)

Abstract

The current therapy for chronic proteinuric nephropathies is angiotensin-converting enzyme inhibitors (ACEi), which slow, but may not halt, the progression of disease, and which may be not effective to the same degree in all patients. In accelerated passive Heymann nephritis (PHN), this study assessed the effect of combining ACEi with angiotensin II receptor antagonist (AIIRA) and with statin that, besides lowering cholesterol, influences inflammatory and fibrogenic processes. Uninephrectomized PHN rats were divided into four groups (n = 10 each) and daily given oral doses of the following: vehicle; 40 mg/L lisinopril; 100 mg/L lisinopril plus L-158,809; 0.3 mg/kg lisinopril plus L-158,809 plus cerivastatin. Treatments started at 2 mo when rats had massive proteinuria and signs of renal injury and lasted until 10 mo. Increases in BP were equally lowered by treatments. ACEi kept proteinuria at levels comparable to pretreatment and numerically lower than vehicle. The addition of AIIRA to lisinopril was more effective, being proteinuria reduced below pretreatment values and significantly lower than vehicle. When cerivastatin was added on top of ACE inhibition and AIIR blockade, urinary protein regressed to normal values and renal failure was prevented. Renal ACE activity was increased three-fold in PHN, it was inhibited by more than 60% after ACEi, and decreased below control values with triple therapy. Cerivastatin inhibited ACE activity by 30%. Glomerulosclerosis, tubular damage and interstitial inflammation were ameliorated by ACEi alone or combined with AIIRA, and prevented by addition of statin. TGF-β1 mRNA upregulation in PHN kidney was partially reduced after ACEi or combined with AIIRA and almost normalized after adding statin. Cerivastatin inhibited TGF-β1 gene upregulation by 25%. These data suggest a possible future strategy to induce remission of proteinuria, lessen renal injury, and protect from loss of function in those patients who do not fully respond to ACEi therapy.

Original languageEnglish
Pages (from-to)2898-2908
Number of pages11
JournalJournal of the American Society of Nephrology
Volume13
Issue number12
DOIs
Publication statusPublished - Dec 2002

Fingerprint

Angiotensin-Converting Enzyme Inhibitors
Lisinopril
Membranous Glomerulonephritis
Kidney
Angiotensin Receptor Antagonists
Proteinuria
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Up-Regulation
Enzyme Therapy
Wounds and Injuries
Therapeutics
Renal Insufficiency
Disease Progression
Reference Values
Cholesterol
Inflammation
Messenger RNA
cerivastatin
Genes
Proteins

ASJC Scopus subject areas

  • Nephrology

Cite this

How to fully protect the kidney in a severe model of progressive nephropathy : A multidrug approach. / Zoja, Carla; Corna, Daniela; Camozzi, Davide; Cattaneo, Dario; Rottoli, Daniela; Batani, Cristian; Zanchi, Cristina; Abbate, Mauro; Remuzzi, Giuseppe.

In: Journal of the American Society of Nephrology, Vol. 13, No. 12, 12.2002, p. 2898-2908.

Research output: Contribution to journalArticle

Zoja, Carla ; Corna, Daniela ; Camozzi, Davide ; Cattaneo, Dario ; Rottoli, Daniela ; Batani, Cristian ; Zanchi, Cristina ; Abbate, Mauro ; Remuzzi, Giuseppe. / How to fully protect the kidney in a severe model of progressive nephropathy : A multidrug approach. In: Journal of the American Society of Nephrology. 2002 ; Vol. 13, No. 12. pp. 2898-2908.
@article{626895f24cda4261a632a9e9d3380402,
title = "How to fully protect the kidney in a severe model of progressive nephropathy: A multidrug approach",
abstract = "The current therapy for chronic proteinuric nephropathies is angiotensin-converting enzyme inhibitors (ACEi), which slow, but may not halt, the progression of disease, and which may be not effective to the same degree in all patients. In accelerated passive Heymann nephritis (PHN), this study assessed the effect of combining ACEi with angiotensin II receptor antagonist (AIIRA) and with statin that, besides lowering cholesterol, influences inflammatory and fibrogenic processes. Uninephrectomized PHN rats were divided into four groups (n = 10 each) and daily given oral doses of the following: vehicle; 40 mg/L lisinopril; 100 mg/L lisinopril plus L-158,809; 0.3 mg/kg lisinopril plus L-158,809 plus cerivastatin. Treatments started at 2 mo when rats had massive proteinuria and signs of renal injury and lasted until 10 mo. Increases in BP were equally lowered by treatments. ACEi kept proteinuria at levels comparable to pretreatment and numerically lower than vehicle. The addition of AIIRA to lisinopril was more effective, being proteinuria reduced below pretreatment values and significantly lower than vehicle. When cerivastatin was added on top of ACE inhibition and AIIR blockade, urinary protein regressed to normal values and renal failure was prevented. Renal ACE activity was increased three-fold in PHN, it was inhibited by more than 60{\%} after ACEi, and decreased below control values with triple therapy. Cerivastatin inhibited ACE activity by 30{\%}. Glomerulosclerosis, tubular damage and interstitial inflammation were ameliorated by ACEi alone or combined with AIIRA, and prevented by addition of statin. TGF-β1 mRNA upregulation in PHN kidney was partially reduced after ACEi or combined with AIIRA and almost normalized after adding statin. Cerivastatin inhibited TGF-β1 gene upregulation by 25{\%}. These data suggest a possible future strategy to induce remission of proteinuria, lessen renal injury, and protect from loss of function in those patients who do not fully respond to ACEi therapy.",
author = "Carla Zoja and Daniela Corna and Davide Camozzi and Dario Cattaneo and Daniela Rottoli and Cristian Batani and Cristina Zanchi and Mauro Abbate and Giuseppe Remuzzi",
year = "2002",
month = "12",
doi = "10.1097/01.ASN.0000034912.55186.EC",
language = "English",
volume = "13",
pages = "2898--2908",
journal = "Journal of the American Society of Nephrology : JASN",
issn = "1046-6673",
publisher = "American Society of Nephrology",
number = "12",

}

TY - JOUR

T1 - How to fully protect the kidney in a severe model of progressive nephropathy

T2 - A multidrug approach

AU - Zoja, Carla

AU - Corna, Daniela

AU - Camozzi, Davide

AU - Cattaneo, Dario

AU - Rottoli, Daniela

AU - Batani, Cristian

AU - Zanchi, Cristina

AU - Abbate, Mauro

AU - Remuzzi, Giuseppe

PY - 2002/12

Y1 - 2002/12

N2 - The current therapy for chronic proteinuric nephropathies is angiotensin-converting enzyme inhibitors (ACEi), which slow, but may not halt, the progression of disease, and which may be not effective to the same degree in all patients. In accelerated passive Heymann nephritis (PHN), this study assessed the effect of combining ACEi with angiotensin II receptor antagonist (AIIRA) and with statin that, besides lowering cholesterol, influences inflammatory and fibrogenic processes. Uninephrectomized PHN rats were divided into four groups (n = 10 each) and daily given oral doses of the following: vehicle; 40 mg/L lisinopril; 100 mg/L lisinopril plus L-158,809; 0.3 mg/kg lisinopril plus L-158,809 plus cerivastatin. Treatments started at 2 mo when rats had massive proteinuria and signs of renal injury and lasted until 10 mo. Increases in BP were equally lowered by treatments. ACEi kept proteinuria at levels comparable to pretreatment and numerically lower than vehicle. The addition of AIIRA to lisinopril was more effective, being proteinuria reduced below pretreatment values and significantly lower than vehicle. When cerivastatin was added on top of ACE inhibition and AIIR blockade, urinary protein regressed to normal values and renal failure was prevented. Renal ACE activity was increased three-fold in PHN, it was inhibited by more than 60% after ACEi, and decreased below control values with triple therapy. Cerivastatin inhibited ACE activity by 30%. Glomerulosclerosis, tubular damage and interstitial inflammation were ameliorated by ACEi alone or combined with AIIRA, and prevented by addition of statin. TGF-β1 mRNA upregulation in PHN kidney was partially reduced after ACEi or combined with AIIRA and almost normalized after adding statin. Cerivastatin inhibited TGF-β1 gene upregulation by 25%. These data suggest a possible future strategy to induce remission of proteinuria, lessen renal injury, and protect from loss of function in those patients who do not fully respond to ACEi therapy.

AB - The current therapy for chronic proteinuric nephropathies is angiotensin-converting enzyme inhibitors (ACEi), which slow, but may not halt, the progression of disease, and which may be not effective to the same degree in all patients. In accelerated passive Heymann nephritis (PHN), this study assessed the effect of combining ACEi with angiotensin II receptor antagonist (AIIRA) and with statin that, besides lowering cholesterol, influences inflammatory and fibrogenic processes. Uninephrectomized PHN rats were divided into four groups (n = 10 each) and daily given oral doses of the following: vehicle; 40 mg/L lisinopril; 100 mg/L lisinopril plus L-158,809; 0.3 mg/kg lisinopril plus L-158,809 plus cerivastatin. Treatments started at 2 mo when rats had massive proteinuria and signs of renal injury and lasted until 10 mo. Increases in BP were equally lowered by treatments. ACEi kept proteinuria at levels comparable to pretreatment and numerically lower than vehicle. The addition of AIIRA to lisinopril was more effective, being proteinuria reduced below pretreatment values and significantly lower than vehicle. When cerivastatin was added on top of ACE inhibition and AIIR blockade, urinary protein regressed to normal values and renal failure was prevented. Renal ACE activity was increased three-fold in PHN, it was inhibited by more than 60% after ACEi, and decreased below control values with triple therapy. Cerivastatin inhibited ACE activity by 30%. Glomerulosclerosis, tubular damage and interstitial inflammation were ameliorated by ACEi alone or combined with AIIRA, and prevented by addition of statin. TGF-β1 mRNA upregulation in PHN kidney was partially reduced after ACEi or combined with AIIRA and almost normalized after adding statin. Cerivastatin inhibited TGF-β1 gene upregulation by 25%. These data suggest a possible future strategy to induce remission of proteinuria, lessen renal injury, and protect from loss of function in those patients who do not fully respond to ACEi therapy.

UR - http://www.scopus.com/inward/record.url?scp=0036891829&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036891829&partnerID=8YFLogxK

U2 - 10.1097/01.ASN.0000034912.55186.EC

DO - 10.1097/01.ASN.0000034912.55186.EC

M3 - Article

C2 - 12444208

AN - SCOPUS:0036891829

VL - 13

SP - 2898

EP - 2908

JO - Journal of the American Society of Nephrology : JASN

JF - Journal of the American Society of Nephrology : JASN

SN - 1046-6673

IS - 12

ER -